GRAVES DISEASE

✓ Medically ReviewedDISEASEID: MDBT0287🚨 TRIAGE: URGENTICD-10: E05.0

📖

Definition

CLINICAL DEFINITION

Graves disease is an autoimmune thyroid condition in which stimulating autoantibodies directed against the TSH receptor cause sustained overproduction of thyroid hormones, typically producing a diffuse goiter and biochemical hyperthyroidism. The diagnosis is established by the combination of suppressed TSH, elevated free T4 and/or free T3, and positive TSH receptor antibodies (TRAb); radioiodine uptake scanning is an alternative confirmatory approach when TRAb testing is unavailable or equivocal. The disease may be accompanied by extrathyroidal manifestations, most commonly Graves orbitopathy, and less frequently thyroid dermopathy and acropachy.

IN PLAIN ENGLISH

Graves disease is a condition where the immune system mistakenly stimulates the thyroid gland to make too much thyroid hormone. This causes symptoms such as a fast heartbeat, weight loss, sweating, and sometimes bulging eyes. It is the most common cause of an overactive thyroid.

COMMON MISCONCEPTION / WHAT IT DOES NOT MEAN

Graves disease is NOT simply any form of hyperthyroidism; it is a specific autoimmune disease defined by TSH receptor antibodies. It is also NOT the same as toxic multinodular goiter or thyroiditis, which can produce thyrotoxicosis through different mechanisms and require different management.

🔤

Word Breakdown

Graves

=Eponymous — derived from the surname of Robert James Graves

Literal Meaning: Named after Robert James Graves, the 19th-century Irish physician who described the condition

🏷️

Abbreviations

GD=Graves Disease — the standard abbreviation used in endocrine and general medical documentation

TRAb=TSH Receptor Antibodies — the pathogenic autoantibodies that confirm the diagnosis

TSI=Thyroid-Stimulating Immunoglobulin — an alternative term for stimulating TSH receptor antibodies

GO=Graves Orbitopathy — the most common extrathyroidal manifestation

🔄

Synonyms & Variants

Toxic Diffuse Goiter›Basedow's Disease›Diffuse Toxic Goiter›

🎯

Category-Specific Context

As a disease, Graves disease is classified within the spectrum of autoimmune thyroid disorders. Its severity ranges from subclinical hyperthyroidism to overt thyrotoxicosis, and it may be complicated by extrathyroidal manifestations such as orbitopathy, dermopathy, and acropachy. Management is stratified by disease activity, presence of complications, patient preference, and pregnancy status.

🏥

Clinical Context & Usage

CLINICAL SETTINGS

Endocrinology Outpatient ClinicGeneral Medicine WardEmergency DepartmentOphthalmology ClinicNuclear Medicine DepartmentAntenatal Clinic

USAGE & DOCUMENTATION NOTES

In clinical documentation, Graves disease is typically recorded as 'Graves disease' with the biochemical status specified, for example, 'Graves disease with overt hyperthyroidism' or 'Graves disease, currently euthyroid on methimazole'. The abbreviation 'GD' is commonly used in endocrine notes and correspondence. TSH receptor antibody titres are often documented as 'TRAb positive' or with the numeric value and assay units. When orbitopathy is present, it is documented separately as 'Graves orbitopathy' with activity and severity descriptors.

🔬

Primary Causes & Pathophysiology

PATHOPHYSIOLOGY

Graves disease arises from a breakdown of immune tolerance that leads to the production of stimulating autoantibodies directed against the TSH receptor on thyroid follicular cells. These antibodies bind to and activate the TSH receptor, mimicking TSH and driving constitutive activation of the cAMP signalling pathway. This results in diffuse hypertrophy and hyperplasia of the thyroid gland, increased thyroid hormone synthesis, and uncontrolled secretion of T4 and T3. The same autoantibodies are thought to contribute to extrathyroidal manifestations by reacting with antigens expressed in orbital fibroblasts and pretibial tissues, promoting local inflammation, glycosaminoglycan accumulation, and tissue remodelling.

PRIMARY CAUSES

Autoimmune stimulation by TSH receptor antibodies

Stimulating TRAb activate the TSH receptor, causing continuous thyroid hormone synthesis and secretion independent of pituitary feedback.

Genetic susceptibility

Polymorphisms in immune-regulatory genes, including HLA and CTLA-4 variants, increase the risk of loss of tolerance to the TSH receptor.

Environmental triggers

Factors such as high iodine intake, smoking, stress, and certain infections may precipitate or exacerbate the autoimmune response in genetically predisposed individuals.

🌍

Epidemiology

Prevalence:Graves disease accounts for approximately 70% of cases of hyperthyroidism in iodine-sufficient regions. The global prevalence of hyperthyroidism is estimated at 0.2–1.3%, and the lifetime risk of Graves disease is approximately 3% in women and 0.5% in men.

Age Group:Most commonly diagnosed in adults aged 20–50 years, with a peak incidence in the fourth and fifth decades. It can occur at any age, including childhood and older adulthood.

Sex Predilection:Female

Geographic Distribution:Graves disease is the predominant cause of hyperthyroidism in iodine-sufficient regions worldwide. The incidence is broadly similar across Europe and North America, with some variation attributable to iodine intake and smoking prevalence.

Red Flags & Triage ★

TRIAGE LEVEL

🚨 URGENT

DO NOT MISS — LIFE-THREATENING PRESENTATIONS

Thyroid storm should be considered in any patient with Graves disease presenting with fever, marked tachycardia, agitation or altered consciousness, and gastrointestinal or hepatic dysfunction; this requires emergency assessment and treatment.
Sight-threatening Graves orbitopathy (dysthyroid optic neuropathy) should be suspected in patients with Graves disease and new visual acuity loss, colour vision impairment, or severe eye pain; urgent ophthalmology referral is indicated.

URGENT EVALUATION TRIGGERS

Fever with severe tachycardia and agitation in a patient with known or suspected Graves disease
New visual loss, diplopia, or severe orbital pain
Chest pain, syncope, or symptoms of heart failure
Severe vomiting, diarrhoea, or jaundice in a thyrotoxic patient

Contraindications & Precautions

CONTRAINDICATIONS

Radioiodine therapy is absolutely contraindicated during pregnancy and breastfeeding
Radioiodine therapy should be avoided in patients with active moderate-to-severe Graves orbitopathy because of the risk of deterioration
Antithyroid drugs should be used with caution in patients with previous agranulocytosis or severe hepatotoxicity attributable to these agents

SPECIAL PRECAUTIONS

Monitor for agranulocytosis and hepatotoxicity in patients receiving methimazole or propylthiouracil
and instruct patients to seek urgent assessment for fever or sore throat
Achieve and maintain euthyroidism in patients with Graves orbitopathy; radioiodine may require glucocorticoid prophylaxis in those with risk factors for orbitopathy deterioration
Counsel women of childbearing potential about contraception and the need to avoid radioiodine from at least 6 months before conception until breastfeeding is complete
Assess thyroid function regularly during pregnancy in women with a history of Graves disease because TRAb can cross the placenta and affect the fetus

Complications

DOWNSTREAM CLINICAL COMPLICATIONS

Graves orbitopathy — autoimmune inflammation of orbital tissues causing proptosis
diplopia
and in severe cases optic neuropathy
Thyroid dermopathy (pretibial myxoedema) — localised mucin deposition in the pretibial skin
almost always accompanying orbitopathy
Acropachy — clubbing of digits with soft-tissue swelling
a rare manifestation associated with severe orbitopathy and dermopathy
Atrial fibrillation — hyperthyroidism increases the risk of this arrhythmia
particularly in older patients
High-output cardiac failure — sustained thyrotoxicosis increases cardiac workload and can precipitate heart failure
Thyroid storm — a life-threatening exacerbation of thyrotoxicosis with multi-organ decompensation

🔀

Confused With (LASA & DDx) ★

CLINICAL DIFFERENTIAL DIAGNOSES (DDx)

Toxic Multinodular Goiter

Key Distinguishing Feature: Hyperthyroidism with nodular thyroid morphology on ultrasound and absent TSH receptor antibodies; radioiodine uptake shows focal or heterogeneous increased uptake.

Painless Thyroiditis

Key Distinguishing Feature: Thyrotoxic phase with low radioiodine uptake and absent TSH receptor antibodies; often followed by transient hypothyroidism.

Factitious Thyrotoxicosis

Key Distinguishing Feature: Exogenous thyroid hormone ingestion with suppressed TSH, low thyroglobulin, and low radioiodine uptake; no goiter or orbitopathy.

💎

Clinical Pearls

💎

TSH receptor antibody testing is the most specific confirmatory test for Graves disease; a positive result in a thyrotoxic patient establishes the diagnosis without requiring radioiodine uptake scanning.

💎

Graves orbitopathy can occur before, during, or after the onset of hyperthyroidism and may follow an independent course; smoking is a major modifiable risk factor for its development and progression.

💎

Propylthiouracil is preferred over methimazole in the first trimester of pregnancy because of the teratogenic risk associated with methimazole, but methimazole is generally preferred in non-pregnant patients because of the hepatotoxicity risk associated with propylthiouracil.

💎

Radioiodine therapy can worsen pre-existing Graves orbitopathy, particularly in smokers and those with high TRAb titres; glucocorticoid prophylaxis should be considered in at-risk patients.

💎

Long-term antithyroid drug therapy (5–10 years) is a reasonable option for patients who wish to avoid definitive therapy and is associated with a lower relapse rate than shorter courses.

📝

Example Usage & SOAP

CLINICAL SENTENCE

"A 34-year-old woman presented with palpitations, heat intolerance, and weight loss; examination revealed a diffuse goiter and bilateral proptosis, and laboratory tests confirmed suppressed TSH with elevated free T4 and positive TSH receptor antibodies, consistent with Graves disease."

IN A SOAP NOTE

S: 34-year-old woman reports 3 months of palpitations, heat intolerance, and unintentional weight loss of 6 kg. O: Heart rate 108 beats/min, blood pressure 138/76 mmHg, diffuse smooth goiter, bilateral proptosis, fine tremor. TSH <0.01 mU/L, free T4 42 pmol/L (reference 10–22), free T3 9.8 pmol/L (reference 3.1–6.8), TRAb positive. A: Graves disease with overt hyperthyroidism and mild Graves orbitopathy. P: Start methimazole 10 mg twice daily and propranolol 20 mg three times daily; counsel on agranulocytosis warning signs; arrange ophthalmology review; discuss definitive treatment options at follow-up.

DIFFERENTIAL DIAGNOSIS CONTEXT

Differential for thyrotoxicosis with a diffuse goiter: (1) Graves disease — positive TRAb, diffuse increased radioiodine uptake, may have orbitopathy; (2) toxic multinodular goiter — nodular morphology on ultrasound, absent TRAb, heterogeneous uptake; (3) painless thyroiditis — low radioiodine uptake, absent TRAb, often transient and followed by hypothyroidism; (4) factitious thyrotoxicosis — low thyroglobulin, absent goiter, low radioiodine uptake.

📊

Classifications & Scoring

GRADING SYSTEM

Clinical Activity Score (CAS) for Graves Orbitopathy

A 7-item or 10-item score assessing inflammatory activity in Graves orbitopathy. A score of 3 or more out of 7 at first examination, or 4 or more out of 10 on repeat examination, indicates active disease.

View Reference ↗

SCORING TOOL

Burch-Wartofsky Point Scale (BWPS) for Thyroid Storm

A clinical scoring system used to estimate the likelihood of thyroid storm in thyrotoxic patients, incorporating thermoregulatory, central nervous system, gastrointestinal, cardiovascular, and precipitant-related parameters. A score of 45 or more is highly suggestive of thyroid storm.

Clinical Calculator ↗

📈

Prognosis

SHORT-TERM OUTCOME

With appropriate antithyroid drug therapy, biochemical euthyroidism is usually achieved within 4–8 weeks, and symptoms improve over weeks to months. Radioiodine or surgery achieves definitive control but requires levothyroxine replacement thereafter.

LONG-TERM PROGNOSIS

Relapse after a 12–18 month course of antithyroid drugs occurs in approximately 50% of patients. Long-term antithyroid drug therapy (5–10 years) is associated with a lower relapse rate of approximately 15%. Definitive therapy with radioiodine or surgery results in permanent hypothyroidism requiring lifelong levothyroxine in most patients. Graves orbitopathy may follow an independent course and can worsen, stabilise, or improve over time.

📚

References & Coding

ICD-10 DIAGNOSTIC CODE

E05.0

LITERATURE CITATIONS & GUIDELINES

[1]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229

[2]Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186. doi:10.1159/000490384

[3]Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol. 2023;11(4):282-298. doi:10.1016/S2213-8587(23)00005-0

[4]Lee SY, Pearce EN. Hyperthyroidism: A Review. JAMA. 2023;330(15):1472-1483. doi:10.1001/jama.2023.19052

MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current clinical diagnostic criteria, institutional protocols, and official guidelines. Medobo is not responsible for clinical decisions made based on this content.